

Official Journal of the Society for Neuro-Oncology since 1997

# NEURO-ONCOLOGY

Volume 15 • Supplement 2 • 2013

---

## CBTRUS

Central Brain Tumor Registry of the United States

Statistical Report Supplement 2013

Primary Brain and Central Nervous System Tumors Diagnosed  
in the United States 2006-2010

---



[neuro-oncology.oxfordjournals.org](http://neuro-oncology.oxfordjournals.org)

Online ISSN: 1523-5866 Print ISSN: 1522-8517

OXFORD  
UNIVERSITY PRESS

OXFORD  OPEN



# NEURO-ONCOLOGY

Founded with a grant from The Pediatric Brain Tumor Foundation of the United States

---

**W. K. Alfred Yung**, *Editor-in-chief*  
**C. David James**, *Executive Editor SNO*  
**Michael Weller**, *Executive Editor EANO*  
**Ryo Nishikawa**, *Executive Editor JSNO*  
**Darell D. Bigner**, *Founding Editor*

**Ann Sutton**, *Managing Editor*  
**Jill Delsigne**, *Assistant Managing Editor*  
**Donna Sims**, *Peer Review Coordinator*

---

*Editorial Board*

Till Acker  
Kenneth Aldape  
Hidefumi Aoyama  
Joachim Baehring  
Karla V. Ballman  
Tracy Batchelor  
Mitchel S. Berger  
Rolf Bjerkvig  
Michael Brada  
Daniel J. Brat  
Jan C. Buckner  
Daniel Cahill  
Steven Carroll  
Maria Castro  
Webster K. Cavenee  
Marc Chamberlain  
Susan M. Chang  
Zhongping Chen  
Shiyuan Cheng  
Lynda Chin  
Olivier Chinot  
E. Antonio Chiocca  
Charles Conrad  
Joseph Costello  
Lisa DeAngelis  
Jonathan L. Finlay

Gaetano Finocchiaro  
Daniel W. Fufts III  
Frank Furnari  
Amar Gajjar  
Eva Galanis  
Stuart A. Grossman  
David H. Gutmann  
Christian Hartmann  
Monika E. Hegi  
Amy Heimberger  
John Henson  
Graeme Hodgson  
Yong-Kil Hong  
Koichi Ichimura  
Robert Jenkins  
Randy Jensen  
Tao Jiang  
Hee-Won Jung  
Tim Kaufmann  
Mark W. Kieran  
Toru Kondo  
Toshihiro Kumabe  
Normand Laperriere  
John Laterra  
Ching Lau  
Peter Lichter  
Keith Ligon

Zhimin Lu  
Luigi Mariani  
Christine Marosi  
Ian McCutcheon  
Roger McLendon  
Minesh Mehta  
Ingo Mellinger  
T. Mikkelsen  
Paul S. Mischel  
Burt Nabors  
Mitsutoshi Nakada  
Do-Hyun Nam  
Hiroko Ohgaki  
Donald O'Rourke  
Andrew Parsa  
Dennis K. Pearl  
Russell O. Pieper  
Heidi Phillips  
Michael D. Prados  
Vinay Puduvalli  
Jasti S. Rao  
David A. Reardon  
Guido Reifenberger  
Jeremy Rich  
James T. Rutka  
John H. Sampson  
Marc Sanson

Jann Sarkaria  
Yutaka Sawamura  
Hideyuki Saya  
Davide Schiffer  
Uwe Schlegel  
Joan Seoane  
Ricardo Soffietti  
Yukihiko Sonoda  
Joachim Steinbach  
Volker W. Stieber  
Roger Stupp  
Shingo Takano  
Martin Taphoorn  
Joerg Tonn  
Martin J. van den Bent  
Michael A. Vogelbaum  
Andreas von Deimling  
Toshihiko Wakabayashi  
William Weiss  
Patrick Wen  
Peter Wesseling  
Manfred Westphal  
Wolfgang Wick  
Ryuya Yamanaka

---

*Neuro-Oncology* Editorial Office  
The University of Texas MD Anderson Cancer Center  
1515 Holcombe Blvd., Unit 1421, Houston, TX 77030

---

# CBTRUS

Central Brain Tumor Registry of the United States



CBTRUS Statistical Report:  
Primary Brain and Central Nervous System Tumors  
Diagnosed in the United States in  
2006–2010

Neuro-Oncology Supplement

Official Journal for the Society of Neuro-Oncology

Volume 15, 2013, Supplement 2

# CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006–2010

Quinn T. Ostrom, M.A., M.P.H.<sup>1,2</sup>

Haley R. Gittleman, M.S.<sup>1,2</sup>

Paul Farah<sup>3</sup>

Annie Ondracek<sup>4</sup>

Yanwen Chen, Ph.D., M.S.<sup>1,2</sup>

Yingli Wolinsky, Ph.D., M.B.A.<sup>1,2</sup>

Nancy E. Stroup, Ph.D.<sup>2</sup>

Carol Kruchko, B.A.<sup>2</sup>

Jill S. Barnholtz-Sloan, Ph.D.<sup>1,2</sup>

## Affiliations

1. Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH USA
2. Central Brain Tumor Registry of the United States, Hinsdale, IL USA
3. Case Western Reserve University, Cleveland, OH USA
4. The Ohio State University, Columbus, OH USA

## ACKNOWLEDGMENTS

This report was prepared by the Central Brain Tumor Registry of the United States (CBTRUS) executive team and the research staff affiliated with the Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine. The CBTRUS data presented in this report were provided through an agreement with the Centers for Disease Control and Prevention (CDC), National Program of Cancer Registries (NPCR). In addition, CBTRUS used data from the research data files of the National Cancer Institute (NCI), Surveillance, Epidemiology, and End Results (SEER) Program. CBTRUS acknowledges and appreciates these contributions to this report and to cancer surveillance in general.

Sources of geographic population-based cancer incidence data included in this report are from the following central cancer registries:

Alabama	Georgia	Maryland	New Mexico <sup>SEER</sup>	South Dakota
Alaska	Hawaii <sup>SEER</sup>	Massachusetts	New York	Tennessee
Arizona	Idaho	Michigan	North Carolina	Texas
Arkansas	Illinois	Mississippi	North Dakota	Utah <sup>SEER</sup>
California	Indiana	Missouri	Ohio	Vermont
Colorado	Iowa <sup>SEER</sup>	Montana	Oklahoma	Virginia
Connecticut <sup>SEER</sup>	Kansas	Nebraska	Oregon	Washington
Delaware	Kentucky	Nevada	Pennsylvania	West Virginia
District of Columbia	Louisiana	New Hampshire	Rhode Island	Wisconsin
Florida	Maine	New Jersey	South Carolina	Wyoming

---

<sup>SEER</sup>Data obtained from the SEER research data files for these population-based cancer registries. All other population-based cancer registry data provided by the NPCR.

We acknowledge the efforts of the hospital tumor registrars, the central cancer registries, the staff from the NPCR and SEER programs whose efforts to collect accurate and complete data have made this report possible. We also are grateful for the three neuropathologists, Drs. Janet Bruner, Roger McLendon, and Tarik Tihan, who reviewed and revised the CBTRUS histology grouping scheme with us, neuropathologist Dr. Mark Cohen for his assistance in guiding editing of the CBTRUS dataset, and for our Board of Directors and Advisors who reviewed this report, especially Drs. Margaret Wrensch, Melissa Bondy, and James Gurney.

### Citation:

Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006–2010. *Neuro-Oncol* 2013 Nov; 15(sup 2): ii1–ii56

# CBTRUS Funding



*Support of the Central Brain Tumor Registry of the United States in 2013 has been provided by the National Brain Tumor Society ([www.braintumor.org](http://www.braintumor.org)), the Pediatric Brain Tumor Foundation ([www.curethekids.org](http://www.curethekids.org)), private donations and from the Centers for Disease Control and Prevention (CDC) under Cooperative Agreement 5U58DP003831-02. The contents in this report are solely the responsibility of the authors and do not necessarily represent the official views of the CDC. The CBTRUS is honored to be included among the research grant recipients of these prestigious organizations.*



CBTRUS would appreciate your help in order to support its database. Contributions are tax deductible and can be mailed to 244 East Ogden Avenue, Suite 116, Hinsdale, Illinois 60521



*Printing of the CBTRUS Statistical Report by Oxford University Press has been provided in 2013 by the American Brain Tumor Association ([www.abta.org](http://www.abta.org)).*

## Subscriptions

A subscription to *Neuro-Oncology* comprises 12 issues. Prices include dispatch by Standard Air. Airmail rates are available on request. *Neuro-Oncology Advance Access* contains papers that have recently been accepted but have not yet been included within an issue. Advance Access is updated daily.

Annual Subscription Rate (Volume 15, 12 issues, 2013)

### Corporate

Print and online access: £528.00/\$1003.00/€792.00

Print edition only: £484.00/\$920.00/€726.00

Site-wide online access only: £418.00/\$920.00/€726.00

### Institutional

Print and online access: £423.00/\$803.00/€634.00

Print edition only: £335.00/\$636.00/€500.00

Site-wide online access only: £387.00/\$737.00/€581.00

### Personal

Print and online access: £186.00/\$355.00/€278.00

Please note: UK£ rate applies to UK and Rest of World, except US and Canada (US\$) and Europe (Eur€). There are other subscription rates available; for a complete listing, please visit [http://www.oxfordjournals.org/our\\_journals/neuonc/access\\_purchase/price\\_list.html](http://www.oxfordjournals.org/our_journals/neuonc/access_purchase/price_list.html).

Full prepayment in the correct currency is required for all orders. Payment should be in US dollars for orders being delivered to the USA or Canada; Euros for orders being delivered within Europe (excluding the UK); GBP Sterling for orders being delivered elsewhere (i.e., not being delivered to USA, Canada, or Europe). All orders should be accompanied by full payment and sent to your nearest Oxford Journals office. Subscriptions are accepted for complete volumes only. Orders are regarded as firm, and payments are not refundable. Our prices include dispatch by Standard Air. Claims must be notified within four months of dispatch/order date (whichever is later). Subscriptions in the EEC may be subject to European VAT. If registered, please supply details to avoid unnecessary charges. For subscriptions that include online versions, a proportion of the subscription price may be subject to UK VAT. Subscribers in Canada, please add GST to the prices quoted. Personal rate subscriptions are only available if payment is made by personal check or credit card, delivery is to a private address, and is for personal use only.

The current year and two previous years issues are available from Oxford Journals. Previous volumes can be obtained from the Periodicals Service Company at <http://www.periodicals.com/oxford.html> or Periodicals Service Company, 11 Main Street, Germantown, NY 12526, USA. E-mail: [psc@periodicals.com](mailto:psc@periodicals.com). Tel: (518) 537-4700. Fax: (518) 537-5899.

## Contact information

Journals Customer Service Department, Oxford Journals, Great Clarendon Street, Oxford OX2 6DP, UK. E-mail: [jnls.cust.serv@oup.com](mailto:jnls.cust.serv@oup.com). Tel: +44 (0)1865 353907.

Fax: +44 (0)1865 353485. **In the Americas, please contact:** Journals Customer Service Department, Oxford Journals, 2001 Evans Road, Cary, NC 27513, USA. E-mail: [jnlorders@oup.com](mailto:jnlorders@oup.com). Tel: (800) 852-7323 (toll-free in USA/Canada) or (919) 677-0977. Fax: (919) 677-1714. **In Japan, please contact:** Journals Customer Service Department, Oxford Journals, 4-5-10-8F Shiba, Minato-ku, Tokyo, 108-8386, Japan. E-mail: [custserv.jp@oup.com](mailto:custserv.jp@oup.com). Tel: (81) 3 5444 5858. Fax: (81) 3 3454 2929.

## Methods of payment

Payment should be made: by cheque (to Oxford Journals, Cashiers Office, Great Clarendon Street, Oxford, OX2 6DP, UK); by bank transfer [to Barclays Bank Plc, Oxford Office, Oxford (bank sort code 20-65-18) (UK); overseas only Swift code BARC GB22 (GB£ Sterling Account no. 70299332, IBAN GB89BARC20651870299332; US\$ Dollars Account no. 66014600, IBAN GB27BARC20651866014600; EU€ EURO Account no. 78923655, IBAN GB16BARC20651878923655]; or by credit card (Mastercard, Visa, Switch or American Express).

## Postal information

*Neuro-Oncology* (ISSN: 1522-8517) is published twelve times per year in January, February, March, April, May, June, July, August, September, October, and December by Oxford University Press, is distributed by 2001 Evans Road, Cary, NC 27513-2009, USA.

Periodicals Postage Paid at Cary, NC. POSTMASTER: Send address changes to *Neuro-Oncology*, Journals Customer Service Department, Oxford University Press, 2001 Evans Road, Cary, NC 27513-2009.

## Environmental and ethical policies

Oxford Journals, a division of Oxford University Press, is committed to working with the global community to bring the highest quality research to the widest possible audience. Oxford Journals will protect the environment by implementing environmentally friendly policies and practices wherever possible. Please see <http://www.oxfordjournals.org/ethicalpolicies.html> for further information on environmental and ethical policies.

## Digital object identifiers

For information on dois and to resolve them, please visit [www.doi.org](http://www.doi.org).

## Supplements, reprints, and corporate sales

For requests from industry and companies regarding supplements, bulk article reprints, sponsored subscriptions, translation opportunities for previously published material, and corporate online opportunities, please e-mail [corporate.services@oup.com](mailto:corporate.services@oup.com), fax +44 (0)1865 353774, or visit [http://www.oxfordjournals.org/corporate\\_services/](http://www.oxfordjournals.org/corporate_services/).

## Permissions

For information on how to request permissions to reproduce articles or information from this journal, please visit [www.oxfordjournals.org/permissions](http://www.oxfordjournals.org/permissions).

## Advertising

Advertising, inserts, and artwork enquiries should be addressed to Advertising and Special Sales, Oxford Journals, Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK. Tel: +44 (0)1865 354767; Fax: +44 (0)1865 353774; E-mail: [jnlsadvertising@oup.com](mailto:jnlsadvertising@oup.com).

## Drug disclaimer

The mention of trade names, commercial products or organizations, and the inclusion of advertisements in the journal does not imply endorsement by the *Neuro-Oncology*, the editors, the editorial board, Oxford University Press, or the organization to which the authors are affiliated. The editors and publishers have taken all reasonable precautions to verify drug names and doses, the results of experimental work, and clinical findings published in the journal. The ultimate responsibility for the use and dosage of drugs mentioned in the journal and in interpretation of published material lies with the medical practitioner, and the editors and publishers cannot accept liability for damages arising from any errors or omissions in the journal. Please inform the editors of any errors.

Copyright © 2013. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.

## Indexing/Abstracting

All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission of the publisher or a license permitting restricted copying issued in the UK by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P 9HE, or in the USA by the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923.

## Instructions for Authors

Full instructions for manuscript preparation and submission can be found at: [http://www.oxfordjournals.org/our\\_journals/neuonc/for\\_authors/](http://www.oxfordjournals.org/our_journals/neuonc/for_authors/).

Typeset by Techset, Chennai, India; Printed by The Sheridan Press, Hanover, PA, USA.

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide.

## EXECUTIVE SUMMARY

CBTRUS (Central Brain Tumor Registry of the United States) is the largest population-based database of primary brain and CNS tumors in the United States, and includes data covering 98% of the US population. As of this year, the report now includes information from 49 state registries and the District of Columbia. This report provides a current comprehensive review of the descriptive epidemiology of primary brain and central nervous system (CNS) tumors in the United States population for the years 2006 through 2010.

### *Incidence*

- The average annual age-adjusted incidence rate of all primary malignant and non-malignant brain and CNS tumors was 21.03 between 2006 and 2010. This is higher in females as compared to males (22.79 versus 19.11), whites as compared to blacks (21.13 versus 20.54), and non-Hispanics as compared to Hispanics (21.30 versus 19.77).
- The average annual age-adjusted incidence rate of all primary malignant brain and CNS tumors was 7.27. The average annual age-adjusted incidence rate of non-malignant brain and CNS tumors was 13.77.
- 34.4% of tumors were malignant and 65.6% were non-malignant. The most commonly occurring malignant brain and CNS tumor was glioblastoma (45.2% of malignant tumors), and the most common non-malignant tumor was meningioma (53.8% of non-malignant tumors).
- The incidence rate of childhood (ages 0-19) primary malignant and non-malignant brain and CNS tumors was 5.26 between 2006 and 2010. This is higher in males as compared to females (5.31 versus 5.21), whites as compared to blacks (5.50 versus 4.03), and non-Hispanics versus Hispanics (5.49 versus 4.46).
- An estimated 65,700 new cases of primary malignant and non-malignant brain and CNS tumors are expected to be diagnosed in the United States in 2013. This includes an expected 22,620 malignant, and 43,110 non-malignant tumors. In 2014, the number of new cases is estimated to be 66,240 (22,810 malignant and 43,430 non-malignant).

### *Mortality*

- There were 68,184 deaths attributed to primary malignant brain and central nervous system between 2006 and 2010. This represents an average annual mortality rate of 4.25 per 100,000.

### *Survival*

- The five-year relative survival rate following diagnosis of a primary malignant brain and CNS tumor was 33.8%. Five-year relative survival was highest for pilocytic astrocytoma (94.4%) and lowest for glioblastoma (4.7%). Survival was higher in younger patients, with a five-year survival of 73.0% for persons aged 0-19, and 5.8% for persons aged 75+.